Monthly
US$200
Billed every month
Nimodipine Oral Solution(尼莫地平口服溶液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applicationsNo longer listed under review: 5 applicationsSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders0View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers11View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 11 distinct approval numbers and 10 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 常州四药制药有限公司 | 国药准字H20254931 | 10ml:60mg | Not stated by source | XC08CAN043X001010101389 | NHSA |
| 江苏恒瑞医药股份有限公司 | 国药准字H20223014 | 20ml:60mg | Not stated by source | XC08CAN043X001010101445 | NHSA |
| 石家庄四药有限公司 | 国药准字H20266179 | 10ml:60mg | Not stated by source | XC08CAN043X001010102763 | NHSA |
| 浙江国镜药业有限公司 | 国药准字H20234476 | 10ml:60mg | Not stated by source | XC08CAN043X001010104634 | NHSA |
| 海南全星制药有限公司 | 国药准字H20253866 | 237ml:1.422g | Not stated by source | XC08CAN043X001010105765 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20244285 | 10ml:60mg | Not stated by source | XC08CAN043X001010181251 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20243913 | 20ml:60mg | Not stated by source | XC08CAN043X001010181979 | NHSA |
| 成都倍特得诺药业有限公司 | 国药准字H20244290 | 237ml:1.422g | Not stated by source | XC08CAN043X001010182338 | NHSA |
| 南京泽恒医药技术开发有限公司 | 国药准字H20253289 | 10ml:60mg | Not stated by source | XC08CAN043X001010183339 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254009 | 10ml:60mg | Not stated by source | XC08CAN043X001010184106 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20244285 | 10ml:60mg | Not stated by source | XC08CAN043X001010281251 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254009 | 10ml:60mg | Not stated by source | XC08CAN043X001010284106 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20244285 | 10ml:60mg | Not stated by source | XC08CAN043X001010381251 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20254010 | 237ml:1.422g | Not stated by source | XC08CAN043X001020184106 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 2 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 黑龙江中桂制药有限公司 | CYHS2600565 | Generic | 2026/02/27 | Not stated by source | CDE |
| 黑龙江中桂制药有限公司 | CYHS2600564 | Generic | 2026/02/27 | Not stated by source | CDE |
| 温岭市创新生物医药科技股份有限公司;万邦德制药集团有限公司 | CYHS2600251 | Generic | 2026/01/22 | Not stated by source | CDE |
| 温岭市创新生物医药科技股份有限公司;万邦德制药集团有限公司 | CYHS2600250 | Generic | 2026/01/22 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 黑龙江中桂制药有限公司 | CYHS2600565 | Generic | 2026/02/27 | Not stated by source | CDE |
| 黑龙江中桂制药有限公司 | CYHS2600564 | Generic | 2026/02/27 | Not stated by source | CDE |
| 温岭市创新生物医药科技股份有限公司;万邦德制药集团有限公司 | CYHS2600251 | Generic | 2026/01/22 | Not stated by source | CDE |
| 温岭市创新生物医药科技股份有限公司;万邦德制药集团有限公司 | CYHS2600250 | Generic | 2026/01/22 | Not stated by source | CDE |
API registrations
Non-component matches: 11 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 尼莫地平 | UNION QUIMICO FARMACEUTICA, S.A. | Y20250000153 | I | Exact ingredient | 2025/06/20 | CDE |
| 尼莫地平 | 河北广祥制药有限公司 | Y20230001169 | A | Exact ingredient | 2026/11/08 | CDE |
| 尼莫地平 | 江苏九旭药业有限公司 | Y20210000068 | A | Exact ingredient | 2025/10/11 | CDE |
| 尼莫地平（预制颗粒） | Bayer Vital GmbH | Y20200001505 | A | Exact ingredient | 2025/12/05 | CDE |
| 尼莫地平 | 山东新华制药股份有限公司 | Y20190009425 | A | Exact ingredient | 2025/02/13 | CDE |
| 尼莫地平 | 天津市中央药业有限公司 | Y20190008603 | A | Exact ingredient | 2025/06/28 | CDE |
| 尼莫地平 | 乐声药业石家庄有限公司 | Y20190005094 | A | Exact ingredient | 2024/12/10 | CDE |
| 尼莫地平 | 西安博爱制药有限责任公司 | Y20190004836 | A | Exact ingredient | 2025/07/28 | CDE |
| 尼莫地平 | 河南科伦药业有限公司 | Y20190004746 | A | Exact ingredient | 2024/11/01 | CDE |
| 尼莫地平 | 亚宝药业集团股份有限公司 | Y20190004586 | A | Exact ingredient | 2026/03/31 | CDE |
| 尼莫地平 | 北京京丰制药（山东）有限公司 | Y20190001823 | A | Exact ingredient | 2025/11/12 | CDE |
| 尼莫地平 | 郑州瑞康制药有限公司 | Y20190001753 | A | Exact ingredient | 2024/11/01 | CDE |
| 尼莫地平（预制颗粒） | Bayer Vital GmbH | Y20190000282 | I | Exact ingredient | 2019/08/12 | CDE |
| 尼莫地平 | 山东新华制药股份有限公司 | Y20180001435 | I | Exact ingredient | 2018/11/13 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/10No longer listed under review
江苏联环药业股份有限公司
CYHS2404433
Fact date: 2026/11/10 · Site observation date: 2026/11/10
Accepted: 2024/12/20
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/10No longer listed under review
江苏联环药业股份有限公司
CYHS2404430
Fact date: 2026/11/10 · Site observation date: 2026/11/10
Accepted: 2024/12/20
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/10No longer listed under review
联环药业（安庆）有限公司;江苏联环药业股份有限公司
CYHB2601545
Fact date: 2026/11/10 · Site observation date: 2026/11/10
Accepted: 2026/08/13
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/10No longer listed under review
联环药业（安庆）有限公司;江苏联环药业股份有限公司
CYHB2601544
Fact date: 2026/11/10 · Site observation date: 2026/11/10
Accepted: 2026/08/13
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/06No longer listed under review
浙江国镜药业有限公司
CYHB2601489
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/08/04
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/04); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 22
NMPA · Table row 22 ↗ View source ↗ -
2026/11/04Supplement delivery
浙江国镜药业有限公司
CYHB2601489
Fact date: 2026/11/04 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 22 ↗ -
2026/08/13Accepted
联环药业（安庆）有限公司;江苏联环药业股份有限公司
CYHB2601545
Fact date: 2026/08/13 · Site observation date: 2026/10/21
View source ↗ -
2026/08/13Accepted
联环药业（安庆）有限公司;江苏联环药业股份有限公司
CYHB2601544
Fact date: 2026/08/13 · Site observation date: 2026/10/21
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Nimodipine Oral Solution
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy